文献速递泌尿生殖与妇科肿瘤放疗

显著淋巴血管间隙浸润对病理淋巴结阴性子宫内膜癌患者是否具有预后意义

Is Substantial Lymphovascular Space Invasion Prognostic in Patients With Pathologically Lymph Node-Negative Endometrial Cancer?
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2023-03-08

本单机构回顾性研究纳入2017至2019年335例病理淋巴结阴性Ⅰ期子宫内膜样子宫内膜癌患者,按三级淋巴血管间隙浸润(LVSI)评分(无、局灶、显著)分析临床结局。显著LVSI患者2年局部无病生存率(LR-DFS)为91.4%,2年无远处转移生存率(DM-DFS)为93.8%,与无LVSI或局灶LVSI患者相似。作者认为需多机构研究验证显著LVSI在该人群中的预后价值。

要点

  • 335例病理淋巴结阴性Ⅰ期子宫内膜样子宫内膜癌患者中17.6%存在显著LVSI。
  • 显著LVSI患者2年LR-DFS为91.4%,无LVSI为92.5%,局灶LVSI为98.0%。
  • 显著LVSI患者2年DM-DFS为93.8%,无LVSI为95.5%,局灶LVSI为93.3%。

核心结论

  • 在本机构研究中,病理淋巴结阴性Ⅰ期子宫内膜癌伴显著LVSI患者的LR-DFS和DM-DFS与无LVSI或局灶LVSI患者相似。
  • 这些发现强调需要多机构研究来验证显著LVSI在该患者人群中的预后价值。

研究设计与样本

  • 单机构回顾性研究,纳入2017年至2019年接受手术分期且病理淋巴结评估阴性的Ⅰ期子宫内膜样子宫内膜癌患者335例。
  • 采用三级LVSI评分(无、局灶或显著)对患者进行分类。
  • 采用Kaplan-Meier法分析临床结局(LR-DFS、DM-DFS和总生存)。

主要发现

  • 显著LVSI存在于17.6%的患者中。
  • 39.7%的患者接受辅助阴道近距离放疗,6.9%的患者接受EBRT。
  • 局灶LVSI患者中81.0%接受阴道近距离放疗。
  • 显著LVSI患者中57.9%仅接受阴道近距离放疗,31.6%接受EBRT。
  • 2年LR-DFS率:无LVSI为92.5%,局灶LVSI为98.0%,显著LVSI为91.4%。

局限性

  • 原文为单机构回顾性研究。
  • 原文结论指出需要多机构研究来验证显著LVSI在该患者人群中的预后价值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Lymphovascular space invasion (LVSI) predicts for higher rates of recurrence and increased mortality in endometrial cancer. Using 3-tier LVSI scoring, a PORTEC-1 and -2 trials analysis demonstrated that substantial LVSI was associated with worse locoregional (LR-DFS) and distant metastasis disease-free survival (DM-DFS), and these patients possibly benefited from external beam radiation therapy (EBRT). Furthermore, LVSI is a predictor for lymph node (LN) involvement, but the significance of substantial LVSI is unknown in patients with a pathologically negative LN assessment. We aimed to evaluate clinical outcomes of these patients in relation to the 3-tier LVSI scoring system. METHODS AND MATERIALS: We performed a single-institutional retrospective review of patients with stage I endometrioid-type endometrial cancer who underwent surgical staging with pathologically negative LN evaluation from 2017 to 2019 with 3-tier LVSI scoring (none, focal, or substantial). Clinical outcomes (LR-DFS, DM-DFS, and overall survival) were analyzed using the Kaplan-Meier method. RESULTS: A total of 335 patients with pathologically LN-negative stage I endometrioid-type endometrial carcinoma were identified. Substantial LVSI was present in 17.6% of patients; 39.7% of patients received adjuvant vaginal brachytherapy and 6.9% of patients received EBRT. Adjuvant radiation treatment varied by LVSI status. In patients with focal LVSI, 81.0% received vaginal brachytherapy. Among patients with substantial LVSI, 57.9% received vaginal brachytherapy alone, and 31.6% of patients received EBRT. The 2-year LR-DFS rates were 92.5%, 98.0%, and 91.4% for no LVSI, focal LVSI, and substantial LVSI, respectively. The 2-year DM-DFS rates were 95.5%, 93.3%, and 93.8% for no LVSI, focal LVSI, and substantial LVSI, respectively. CONCLUSIONS: In our institutional study, patients with pathologically LN-negative stage I endometrial cancer with substantial LVSI had similar rates of LR-DFS and DM-DFS compared with patients with none or focal LVSI. These findings highlight the need for multi-institutional studies to validate the prognostic value of substantial LVSI in this patient population.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Pifer PM, Jaishankar S, Bhargava R, et al. Is Substantial Lymphovascular Space Invasion Prognostic in Patients With Pathologically Lymph Node-Negative Endometrial Cancer? Int J Radiat Oncol Biol Phys. 2023. PMID: 36893818. doi:10.1016/j.ijrobp.2023.02.053

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。